Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
INSY's Cash to Debt is ranked higher than
95% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. INSY: No Debt )
Ranked among companies with meaningful Cash to Debt only.
INSY' s 10-Year Cash to Debt Range
Min: 0.01  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.74
INSY's Equity to Asset is ranked higher than
57% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. INSY: 0.74 )
Ranked among companies with meaningful Equity to Asset only.
INSY' s 10-Year Equity to Asset Range
Min: -3.45  Med: 0.81 Max: 0.98
Current: 0.74
-3.45
0.98
Interest Coverage No Debt
INSY's Interest Coverage is ranked higher than
91% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. INSY: No Debt )
Ranked among companies with meaningful Interest Coverage only.
INSY' s 10-Year Interest Coverage Range
Min: 35.09  Med: 10000.00 Max: 9999.99
Current: No Debt
35.09
9999.99
F-Score: 5
Z-Score: 22.62
M-Score: -2.07
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 21.87
INSY's Operating margin (%) is ranked higher than
87% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. INSY: 21.87 )
Ranked among companies with meaningful Operating margin (%) only.
INSY' s 10-Year Operating margin (%) Range
Min: -324863.64  Med: -783.34 Max: 56.36
Current: 21.87
-324863.64
56.36
Net-margin (%) 13.25
INSY's Net-margin (%) is ranked higher than
82% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. INSY: 13.25 )
Ranked among companies with meaningful Net-margin (%) only.
INSY' s 10-Year Net-margin (%) Range
Min: -301890.91  Med: -966.67 Max: 40.67
Current: 13.25
-301890.91
40.67
ROE (%) 22.05
INSY's ROE (%) is ranked higher than
92% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. INSY: 22.05 )
Ranked among companies with meaningful ROE (%) only.
INSY' s 10-Year ROE (%) Range
Min: -223.53  Med: -54.60 Max: 545.67
Current: 22.05
-223.53
545.67
ROA (%) 16.83
INSY's ROA (%) is ranked higher than
94% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. INSY: 16.83 )
Ranked among companies with meaningful ROA (%) only.
INSY' s 10-Year ROA (%) Range
Min: -118.94  Med: -54.05 Max: 67.69
Current: 16.83
-118.94
67.69
ROC (Joel Greenblatt) (%) 123.51
INSY's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. INSY: 123.51 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
INSY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2087.93  Med: -1339.34 Max: 775
Current: 123.51
-2087.93
775
» INSY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

INSY Guru Trades in Q3 2014

Chase Coleman 300,000 sh (New)
Steven Cohen 675,765 sh (+300.57%)
Paul Tudor Jones 22,394 sh (+27.05%)
Joel Greenblatt Sold Out
» More
Q4 2014

INSY Guru Trades in Q4 2014

Chase Coleman Sold Out
Steven Cohen 603,750 sh (-10.66%)
Paul Tudor Jones 12,448 sh (-44.41%)
» More
Q1 2015

INSY Guru Trades in Q1 2015

Jim Simons 15,900 sh (New)
Paul Tudor Jones 4,570 sh (-63.29%)
Steven Cohen 32,600 sh (-94.60%)
» More
Q2 2015

INSY Guru Trades in Q2 2015

Jim Simons 140,700 sh (+784.91%)
Paul Tudor Jones 14,030 sh (+207.00%)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with INSY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 69.30
INSY's P/E(ttm) is ranked lower than
73% of the 220 Companies
in the Global Biotechnology industry.

( Industry Median: 33.70 vs. INSY: 69.30 )
Ranked among companies with meaningful P/E(ttm) only.
INSY' s 10-Year P/E(ttm) Range
Min: 17.67  Med: 38.52 Max: 2102.43
Current: 69.3
17.67
2102.43
Forward P/E 15.77
INSY's Forward P/E is ranked higher than
74% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 23.42 vs. INSY: 15.77 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 67.70
INSY's PE(NRI) is ranked lower than
73% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 33.30 vs. INSY: 67.70 )
Ranked among companies with meaningful PE(NRI) only.
INSY' s 10-Year PE(NRI) Range
Min: 17.8  Med: 38.24 Max: 735.85
Current: 67.7
17.8
735.85
P/B 11.87
INSY's P/B is ranked lower than
83% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. INSY: 11.87 )
Ranked among companies with meaningful P/B only.
INSY' s 10-Year P/B Range
Min: 0.05  Med: 1.75 Max: 19.89
Current: 11.87
0.05
19.89
P/S 9.17
INSY's P/S is ranked higher than
53% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. INSY: 9.17 )
Ranked among companies with meaningful P/S only.
INSY' s 10-Year P/S Range
Min: 1.74  Med: 467.70 Max: 15230.1
Current: 9.17
1.74
15230.1
PFCF 64.79
INSY's PFCF is ranked lower than
65% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 40.25 vs. INSY: 64.79 )
Ranked among companies with meaningful PFCF only.
INSY' s 10-Year PFCF Range
Min: 30.12  Med: 62.64 Max: 163.52
Current: 64.79
30.12
163.52
POCF 41.54
INSY's POCF is ranked lower than
59% of the 202 Companies
in the Global Biotechnology industry.

( Industry Median: 32.50 vs. INSY: 41.54 )
Ranked among companies with meaningful POCF only.
INSY' s 10-Year POCF Range
Min: 21.81  Med: 39.12 Max: 1030.7
Current: 41.54
21.81
1030.7
EV-to-EBIT 38.48
INSY's EV-to-EBIT is ranked lower than
59% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 26.88 vs. INSY: 38.48 )
Ranked among companies with meaningful EV-to-EBIT only.
INSY' s 10-Year EV-to-EBIT Range
Min: -83.2  Med: 0.50 Max: 103.5
Current: 38.48
-83.2
103.5
Current Ratio 2.95
INSY's Current Ratio is ranked lower than
62% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. INSY: 2.95 )
Ranked among companies with meaningful Current Ratio only.
INSY' s 10-Year Current Ratio Range
Min: 0.14  Med: 6.99 Max: 318.82
Current: 2.95
0.14
318.82
Quick Ratio 2.42
INSY's Quick Ratio is ranked lower than
65% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. INSY: 2.42 )
Ranked among companies with meaningful Quick Ratio only.
INSY' s 10-Year Quick Ratio Range
Min: 0.06  Med: 6.99 Max: 318.82
Current: 2.42
0.06
318.82
Days Inventory 455.28
INSY's Days Inventory is ranked lower than
94% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 122.55 vs. INSY: 455.28 )
Ranked among companies with meaningful Days Inventory only.
INSY' s 10-Year Days Inventory Range
Min: 169.77  Med: 355.08 Max: 1095
Current: 455.28
169.77
1095
Days Sales Outstanding 52.31
INSY's Days Sales Outstanding is ranked higher than
60% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. INSY: 52.31 )
Ranked among companies with meaningful Days Sales Outstanding only.
INSY' s 10-Year Days Sales Outstanding Range
Min: 0.37  Med: 25.57 Max: 72.85
Current: 52.31
0.37
72.85

Valuation & Return

vs
industry
vs
history
Price/Net Cash 54.16
INSY's Price/Net Cash is ranked lower than
94% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. INSY: 54.16 )
Ranked among companies with meaningful Price/Net Cash only.
INSY' s 10-Year Price/Net Cash Range
Min: 1  Med: 6.52 Max: 69.25
Current: 54.16
1
69.25
Price/Net Current Asset Value 18.97
INSY's Price/Net Current Asset Value is ranked lower than
82% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. INSY: 18.97 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
INSY' s 10-Year Price/Net Current Asset Value Range
Min: 0.98  Med: 6.75 Max: 91.93
Current: 18.97
0.98
91.93
Price/Tangible Book 11.82
INSY's Price/Tangible Book is ranked lower than
78% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. INSY: 11.82 )
Ranked among companies with meaningful Price/Tangible Book only.
INSY' s 10-Year Price/Tangible Book Range
Min: 0.62  Med: 6.23 Max: 84.37
Current: 11.82
0.62
84.37
Price/Projected FCF 13.02
INSY's Price/Projected FCF is ranked lower than
76% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. INSY: 13.02 )
Ranked among companies with meaningful Price/Projected FCF only.
INSY' s 10-Year Price/Projected FCF Range
Min: 2.09  Med: 7.37 Max: 86.75
Current: 13.02
2.09
86.75
Price/Median PS Value 0.02
INSY's Price/Median PS Value is ranked higher than
99% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. INSY: 0.02 )
Ranked among companies with meaningful Price/Median PS Value only.
INSY' s 10-Year Price/Median PS Value Range
Min: 0.01  Med: 0.21 Max: 81.51
Current: 0.02
0.01
81.51
Price/Graham Number 5.92
INSY's Price/Graham Number is ranked lower than
75% of the 173 Companies
in the Global Biotechnology industry.

( Industry Median: 3.26 vs. INSY: 5.92 )
Ranked among companies with meaningful Price/Graham Number only.
INSY' s 10-Year Price/Graham Number Range
Min: 2.83  Med: 5.24 Max: 8.79
Current: 5.92
2.83
8.79
Earnings Yield (Greenblatt) (%) 2.62
INSY's Earnings Yield (Greenblatt) (%) is ranked higher than
83% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. INSY: 2.62 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
INSY' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1  Med: 147.70 Max: 3595.1
Current: 2.62
1
3595.1

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 310 402 480 582
EPS($) 1.50 2.13 4.24 5.58
EPS without NRI($) 1.50 2.13 4.24 5.58

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NPR1.Germany,
Insys Therapeutics Inc was incorporated in Delaware in June 1990. The Company is a commercial-stage specialty pharmaceutical company. It develops and commercializes supportive care products. The Company has two marketed products Subsys and Dronabinol SG Capsule. Subsys, a proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients and Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment of chemotherapy-induced nausea and vomiting, or CINV, and anorexia associated with weight loss in patients with AIDS. It markets Subsys through an incentive-based sales model. Dronabinol SG Capsule is a dronabinol soft gelatin capsule that is a generic equivalent to Marinol, an approved second-line treatment for chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS, offered in 2.5, 5.0 and 10.0 milligram dosages. The Company produces the Active Pharmaceutical Ingredient (API) for Dronabinol SG Capsule at its U.S.-based, state-of-the-art dronabinol manufacturing facility. The Company is subject to regulation by the FDA.
» More Articles for INSY

Headlines

Articles On GuruFocus.com
Insys Therapeutics to Present at 10th Annual Wells Fargo Healthcare Conference Sep 01 2015 
Insys Therapeutics, Inc. Files Citizen Petition With the Drug Enforcement Administration (DEA) to Re Aug 18 2015 
Insys Therapeutics' Dronabinol Oral Solution NDA Accepted for Filing by FDA Aug 17 2015 
Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol for the T Aug 04 2015 
Insys Therapeutics to Report Second Quarter 2015 Results Jul 23 2015 
Insys Therapeutics Receives FDA Orphan Drug Designation for Its Liposomal Encapsulated Paclitaxel fo Jan 26 2015 
Insys Therapeutics to Initiate Five Phase III Clinical Trials in 2015 Jan 12 2015 
Insys Therapeutics to Present at 33rd Annual J.P. Morgan Healthcare Conference Jan 05 2015 
Insys Therapeutics Receives FDA Orphan Drug Designation for Liposome Entrapped Paclitaxel as a Poten Dec 09 2014 
Parallel Comparison Analyses Confirm That Insys Therapeutics' Synthetic CBD Is Identical in Chemical Dec 04 2014 

More From Other Websites
Cannabis social network MassRoots applies for Nasdaq listing Sep 02 2015
Falling Earnings Estimates Signal Weakness Ahead for INSYS Therapeutics (INSY) Sep 01 2015
Insys Therapeutics to Present at 10th Annual Wells Fargo Healthcare Conference Sep 01 2015
Insys Therapeutics to Present at 10th Annual Wells Fargo Healthcare Conference Sep 01 2015
INSYS Therapeutics, Inc. Earnings Q2, 2015 Aug 28 2015
INSYS THERAPEUTICS, INC. Files SEC form 8-K, Other Events Aug 27 2015
Insys Files CP; Dronabinol Oral Solution under FDA Review Aug 19 2015
INSYS THERAPEUTICS, INC. Financials Aug 18 2015
Insys Therapeutics, Inc. Files Citizen Petition With the Drug Enforcement Administration (DEA) to... Aug 18 2015
Insys Therapeutics, Inc. Files Citizen Petition With the Drug Enforcement Administration (DEA) to... Aug 18 2015
Insys Therapeutics' Dronabinol Oral Solution NDA Accepted for Filing by FDA Aug 17 2015
Insys Therapeutics' Dronabinol Oral Solution NDA Accepted for Filing by FDA Aug 17 2015
Healthcare Fund Consonance Capital’s Top Picks For Q3 Following Monster First Half Aug 15 2015
Edited Transcript of INSY earnings conference call or presentation 6-Aug-15 2:00pm GMT Aug 07 2015
INSYS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 06 2015
Insys Therapeutics Reports Second Quarter 2015 Results Aug 06 2015
Q2 2015 INSYS Therapeutics Inc Earnings Release - Before Market Open Aug 06 2015
Insys Therapeutics misses 2Q profit forecasts Aug 06 2015
Insys Therapeutics misses 2Q profit forecasts Aug 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK